Hemab's sutacimig cuts prothrombin time by more than 50% in first two Phase 2b participants

• Hemab Therapeutics will present sutacimig clinical results and HMB-003 preclinical data at the ASH meeting December 12-15, 2026.
• Initial Phase 2b results in two participants with severe congenital Factor VII deficiency showed sutacimig shortened blood-clotting time following a single dose.
• Available data showed sustained accumulation of endogenous Factor VII; adverse events were low grade and assessed as unrelated to treatment.
• Preclinical testing showed HMB-003 reduced severe menstrual bleeding in monkeys, supporting its potential as a non-hormonal treatment for heavy menstrual bleeding.
• A Phase 1 trial of HMB-003 in healthy volunteers is ongoing, with initial clinical data expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040905PRIMZONEFULLFEED9870048) on November 04, 2026, and is solely responsible for the information contained therein.